 | • レポートコード：GIR-105X09741 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、イピリムマブのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。イピリムマブの種類別市場規模（PD-L1拮抗薬、CTLA4拮抗薬、免疫チェックポイント阻害剤、その他）、用途別市場規模（がん、黒色腫）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・イピリムマブの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Gilead、BMS、Ono、Roche、Prestige BioPharma、Avacta、Baxter、Shenyang Sansheng Pharmaceutical ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：PD-L1拮抗薬、CTLA4拮抗薬、免疫チェックポイント阻害剤、その他 ・用途別分析2016年-2026年：がん、黒色腫 ・イピリムマブの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・イピリムマブのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・イピリムマブのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・イピリムマブの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・イピリムマブの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Ipilimumab market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Ipilimumab size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Ipilimumab market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Ipilimumab market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
PD – L1 Antagonists
CTLA4 Antagonists
Immunocheckpoint Inhibitors
Other
Market segment by Application can be divided into
Cancer
Melanoma
The key market players for global Ipilimumab market are listed below:
Gilead
BMS
Ono
Roche
Prestige BioPharma
Avacta
Baxter
Shenyang Sansheng Pharmaceutical
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Ipilimumab product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Ipilimumab, with price, sales, revenue and global market share of Ipilimumab in 2018 and 2019.
Chapter 3, the Ipilimumab competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Ipilimumab breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Ipilimumab market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Ipilimumab sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Ipilimumab Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Ipilimumab Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 PD – L1 Antagonists
1.2.3 CTLA4 Antagonists
1.2.4 Immunocheckpoint Inhibitors
1.2.5 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Ipilimumab Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Cancer
1.3.3 Melanoma
1.4 Global Ipilimumab Market Size & Forecast
1.4.1 Global Ipilimumab Sales in Value (2016-2026))
1.4.2 Global Ipilimumab Sales in Volume (2016-2026)
1.4.3 Global Ipilimumab Price by Type (2016-2026) & (US$/G)
1.5 Global Ipilimumab Production Capacity Analysis
1.5.1 Global Ipilimumab Total Production Capacity (2016-2026)
1.5.2 Global Ipilimumab Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Ipilimumab Market Drivers
1.6.2 Ipilimumab Market Restraints
1.6.3 Ipilimumab Trends Analysis
2 Manufacturers Profiles
2.1 Gilead
2.1.1 Gilead Details
2.1.2 Gilead Major Business
2.1.3 Gilead Ipilimumab Product and Services
2.1.4 Gilead Ipilimumab Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 BMS
2.2.1 BMS Details
2.2.2 BMS Major Business
2.2.3 BMS Ipilimumab Product and Services
2.2.4 BMS Ipilimumab Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Ono
2.3.1 Ono Details
2.3.2 Ono Major Business
2.3.3 Ono Ipilimumab Product and Services
2.3.4 Ono Ipilimumab Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche Ipilimumab Product and Services
2.4.4 Roche Ipilimumab Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Prestige BioPharma
2.5.1 Prestige BioPharma Details
2.5.2 Prestige BioPharma Major Business
2.5.3 Prestige BioPharma Ipilimumab Product and Services
2.5.4 Prestige BioPharma Ipilimumab Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Avacta
2.6.1 Avacta Details
2.6.2 Avacta Major Business
2.6.3 Avacta Ipilimumab Product and Services
2.6.4 Avacta Ipilimumab Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Baxter
2.7.1 Baxter Details
2.7.2 Baxter Major Business
2.7.3 Baxter Ipilimumab Product and Services
2.7.4 Baxter Ipilimumab Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Shenyang Sansheng Pharmaceutical
2.8.1 Shenyang Sansheng Pharmaceutical Details
2.8.2 Shenyang Sansheng Pharmaceutical Major Business
2.8.3 Shenyang Sansheng Pharmaceutical Ipilimumab Product and Services
2.8.4 Shenyang Sansheng Pharmaceutical Ipilimumab Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Ipilimumab Sales by Manufacturer
3.1 Global Ipilimumab Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Ipilimumab Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Ipilimumab
3.4 Market Concentration Rate
3.4.1 Top 3 Ipilimumab Manufacturer Market Share
3.4.2 Top 6 Ipilimumab Manufacturer Market Share
3.5 Global Ipilimumab Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Ipilimumab Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Ipilimumab Market Size by Region
4.1.1 Global Ipilimumab Sales in Volume by Region (2016-2026)
4.1.2 Global Ipilimumab Revenue by Region (2016-2026)
4.2 North America Ipilimumab Revenue (2016-2026)
4.3 Europe Ipilimumab Revenue (2016-2026)
4.4 Asia-Pacific Ipilimumab Revenue (2016-2026)
4.5 South America Ipilimumab Revenue (2016-2026)
4.6 Middle East and Africa Ipilimumab Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Ipilimumab Sales in Volume by Type (2016-2026)
5.2 Global Ipilimumab Revenue by Type (2016-2026)
5.3 Global Ipilimumab Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Ipilimumab Sales in Volume by Application (2016-2026)
6.2 Global Ipilimumab Revenue by Application (2016-2026)
6.3 Global Ipilimumab Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Ipilimumab Sales by Type (2016-2026)
7.2 North America Ipilimumab Sales by Application (2016-2026)
7.3 North America Ipilimumab Market Size by Country
7.3.1 North America Ipilimumab Sales in Volume by Country (2016-2026)
7.3.2 North America Ipilimumab Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Ipilimumab Sales by Type (2016-2026)
8.2 Europe Ipilimumab Sales by Application (2016-2026)
8.3 Europe Ipilimumab Market Size by Country
8.3.1 Europe Ipilimumab Sales in Volume by Country (2016-2026)
8.3.2 Europe Ipilimumab Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Ipilimumab Sales by Type (2016-2026)
9.2 Asia-Pacific Ipilimumab Sales by Application (2016-2026)
9.3 Asia-Pacific Ipilimumab Market Size by Region
9.3.1 Asia-Pacific Ipilimumab Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Ipilimumab Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Ipilimumab Sales by Type (2016-2026)
10.2 South America Ipilimumab Sales by Application (2016-2026)
10.3 South America Ipilimumab Market Size by Country
10.3.1 South America Ipilimumab Sales in Volume by Country (2016-2026)
10.3.2 South America Ipilimumab Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Ipilimumab Sales by Type (2016-2026)
11.2 Middle East & Africa Ipilimumab Sales by Application (2016-2026)
11.3 Middle East & Africa Ipilimumab Market Size by Country
11.3.1 Middle East & Africa Ipilimumab Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Ipilimumab Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Ipilimumab Typical Distributors
12.3 Ipilimumab Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Ipilimumab Revenue by Type, (USD Million), 2021-2026
Table 2. Global Ipilimumab Revenue by Application, (USD Million), 2021-2026
Table 3. Gilead Basic Information, Manufacturing Base and Competitors
Table 4. Gilead Major Business
Table 5. Gilead Ipilimumab Product and Services
Table 6. Gilead Ipilimumab Sales (KG), Price (US$/G), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. BMS Basic Information, Manufacturing Base and Competitors
Table 8. BMS Major Business
Table 9. BMS Ipilimumab Product and Services
Table 10. BMS Ipilimumab Sales (KG), Price (US$/G), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Ono Basic Information, Manufacturing Base and Competitors
Table 12. Ono Major Business
Table 13. Ono Ipilimumab Product and Services
Table 14. Ono Ipilimumab Sales (KG), Price (US$/G), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Roche Basic Information, Manufacturing Base and Competitors
Table 16. Roche Major Business
Table 17. Roche Ipilimumab Product and Services
Table 18. Roche Ipilimumab Sales (KG), Price (US$/G), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Prestige BioPharma Basic Information, Manufacturing Base and Competitors
Table 20. Prestige BioPharma Major Business
Table 21. Prestige BioPharma Ipilimumab Product and Services
Table 22. Prestige BioPharma Ipilimumab Sales (KG), Price (US$/G), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Avacta Basic Information, Manufacturing Base and Competitors
Table 24. Avacta Major Business
Table 25. Avacta Ipilimumab Product and Services
Table 26. Avacta Ipilimumab Sales (KG), Price (US$/G), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Baxter Basic Information, Manufacturing Base and Competitors
Table 28. Baxter Major Business
Table 29. Baxter Ipilimumab Product and Services
Table 30. Baxter Ipilimumab Sales (KG), Price (US$/G), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Shenyang Sansheng Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 32. Shenyang Sansheng Pharmaceutical Major Business
Table 33. Shenyang Sansheng Pharmaceutical Ipilimumab Product and Services
Table 34. Shenyang Sansheng Pharmaceutical Ipilimumab Sales (KG), Price (US$/G), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Global Ipilimumab Sales by Manufacturer (2019-2021e) & (KG)
Table 36. Global Ipilimumab Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 37. Market Position of Manufacturers in Ipilimumab, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 38. Global Ipilimumab Production Capacity by Company, (KG): 2020 VS 2021
Table 39. Head Office and Ipilimumab Production Site of Key Manufacturer
Table 40. Ipilimumab New Entrant and Capacity Expansion Plans
Table 41. Ipilimumab Mergers & Acquisitions in the Past Five Years
Table 42. Global Ipilimumab Sales by Region (2016-2021e) & (KG)
Table 43. Global Ipilimumab Sales by Region (2021-2026) & (KG)
Table 44. Global Ipilimumab Revenue by Region (2016-2021e) & (USD Million)
Table 45. Global Ipilimumab Revenue by Region (2021-2026) & (USD Million)
Table 46. Global Ipilimumab Sales by Type (2016-2021e) & (KG)
Table 47. Global Ipilimumab Sales by Type (2021-2026) & (KG)
Table 48. Global Ipilimumab Revenue by Type (2016-2021e) & (USD Million)
Table 49. Global Ipilimumab Revenue by Type (2021-2026) & (USD Million)
Table 50. Global Ipilimumab Price by Type (2016-2021e) & (US$/G)
Table 51. Global Ipilimumab Price by Type (2021-2026) & (US$/G)
Table 52. Global Ipilimumab Sales by Application (2016-2021e) & (KG)
Table 53. Global Ipilimumab Sales by Application (2021-2026) & (KG)
Table 54. Global Ipilimumab Revenue by Application (2016-2021e) & (USD Million)
Table 55. Global Ipilimumab Revenue by Application (2021-2026) & (USD Million)
Table 56. Global Ipilimumab Price by Application (2016-2021e) & (US$/G)
Table 57. Global Ipilimumab Price by Application (2021-2026) & (US$/G)
Table 58. North America Ipilimumab Sales by Country (2016-2021e) & (KG)
Table 59. North America Ipilimumab Sales by Country (2021-2026) & (KG)
Table 60. North America Ipilimumab Revenue by Country (2016-2021e) & (USD Million)
Table 61. North America Ipilimumab Revenue by Country (2021-2026) & (USD Million)
Table 62. North America Ipilimumab Sales by Type (2016-2021e) & (KG)
Table 63. North America Ipilimumab Sales by Type (2021-2026) & (KG)
Table 64. North America Ipilimumab Sales by Application (2016-2021e) & (KG)
Table 65. North America Ipilimumab Sales by Application (2021-2026) & (KG)
Table 66. Europe Ipilimumab Sales by Country (2016-2021e) & (KG)
Table 67. Europe Ipilimumab Sales by Country (2021-2026) & (KG)
Table 68. Europe Ipilimumab Revenue by Country (2016-2021e) & (USD Million)
Table 69. Europe Ipilimumab Revenue by Country (2021-2026) & (USD Million)
Table 70. Europe Ipilimumab Sales by Type (2016-2021e) & (KG)
Table 71. Europe Ipilimumab Sales by Type (2021-2026) & (KG)
Table 72. Europe Ipilimumab Sales by Application (2016-2021e) & (KG)
Table 73. Europe Ipilimumab Sales by Application (2021-2026) & (KG)
Table 74. Asia-Pacific Ipilimumab Sales by Region (2016-2021e) & (KG)
Table 75. Asia-Pacific Ipilimumab Sales by Region (2021-2026) & (KG)
Table 76. Asia-Pacific Ipilimumab Revenue by Region (2016-2021e) & (USD Million)
Table 77. Asia-Pacific Ipilimumab Revenue by Region (2021-2026) & (USD Million)
Table 78. Asia-Pacific Ipilimumab Sales by Type (2016-2021e) & (KG)
Table 79. Asia-Pacific Ipilimumab Sales by Type (2021-2026) & (KG)
Table 80. Asia-Pacific Ipilimumab Sales by Application (2016-2021e) & (KG)
Table 81. Asia-Pacific Ipilimumab Sales by Application (2021-2026) & (KG)
Table 82. South America Ipilimumab Sales by Country (2016-2021e) & (KG)
Table 83. South America Ipilimumab Sales by Country (2021-2026) & (KG)
Table 84. South America Ipilimumab Revenue by Country (2016-2021e) & (USD Million)
Table 85. South America Ipilimumab Revenue by Country (2021-2026) & (USD Million)
Table 86. South America Ipilimumab Sales by Type (2016-2021e) & (KG)
Table 87. South America Ipilimumab Sales by Type (2021-2026) & (KG)
Table 88. South America Ipilimumab Sales by Application (2016-2021e) & (KG)
Table 89. South America Ipilimumab Sales by Application (2021-2026) & (KG)
Table 90. Middle East & Africa Ipilimumab Sales by Country (2016-2021e) & (KG)
Table 91. Middle East & Africa Ipilimumab Sales by Country (2021-2026) & (KG)
Table 92. Middle East & Africa Ipilimumab Revenue by Country (2016-2021e) & (USD Million)
Table 93. Middle East & Africa Ipilimumab Revenue by Country (2021-2026) & (USD Million)
Table 94. Middle East & Africa Ipilimumab Sales by Type (2016-2021e) & (KG)
Table 95. Middle East & Africa Ipilimumab Sales by Type (2021-2026) & (KG)
Table 96. Middle East & Africa Ipilimumab Sales by Application (2016-2021e) & (KG)
Table 97. Middle East & Africa Ipilimumab Sales by Application (2021-2026) & (KG)
Table 98. Direct Channel Pros & Cons
Table 99. Indirect Channel Pros & Cons
Table 100. Ipilimumab Typical Distributors
Table 101. Ipilimumab Typical Customers
List of Figures
Figure 1. Ipilimumab Picture
Figure 2. Global Ipilimumab Sales Market Share by Type in 2020
Figure 3. PD - L1 Antagonists
Figure 4. CTLA4 Antagonists
Figure 5. Immunocheckpoint Inhibitors
Figure 6. Other
Figure 7. Global Ipilimumab Sales Market Share by Application in 2020
Figure 8. Cancer
Figure 9. Melanoma
Figure 10. Global Ipilimumab Market Size, (USD Million) & (KG): 2020 VS 2021 VS 2026
Figure 11. Global Ipilimumab Market Size and Forecast (2016-2026) & (USD Million)
Figure 12. Global Ipilimumab Sales (2016-2026) & (KG)
Figure 13. Global Ipilimumab Price by Type (2016-2026) & (US$/G)
Figure 14. Global Ipilimumab Production Capacity (2016-2026) & (KG)
Figure 15. Global Ipilimumab Production Capacity by Geographic Region: 2020 VS 2021
Figure 16. Ipilimumab Market Drivers
Figure 17. Ipilimumab Market Restraints
Figure 18. Ipilimumab Market Trends
Figure 19. Global Ipilimumab Sales Market Share by Manufacturer in 2020
Figure 20. Global Ipilimumab Revenue Market Share by Manufacturer in 2020
Figure 21. Ipilimumab Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 22. Top 3 Ipilimumab Manufacturer (Revenue) Market Share in 2020
Figure 23. Top 6 Ipilimumab Manufacturer (Revenue) Market Share in 2020
Figure 24. Global Ipilimumab Sales Market Share by Region (2016-2026)
Figure 25. Global Ipilimumab Revenue Market Share by Region (2016-2026)
Figure 26. North America Ipilimumab Revenue (2016-2026) & (USD Million)
Figure 27. Europe Ipilimumab Revenue (2016-2026) & (USD Million)
Figure 28. Asia-Pacific Ipilimumab Revenue (2016-2026) & (USD Million)
Figure 29. South America Ipilimumab Revenue (2016-2026) & (USD Million)
Figure 30. Middle East & Africa Ipilimumab Revenue (2016-2026) & (USD Million)
Figure 31. Global Ipilimumab Sales Market Share by Type (2016-2026)
Figure 32. Global Ipilimumab Revenue Market Share by Type (2016-2026)
Figure 33. Global Ipilimumab Price by Type (2016-2026) & (US$/G)
Figure 34. Global Ipilimumab Sales Market Share by Application (2016-2026)
Figure 35. Global Ipilimumab Revenue Market Share by Application (2016-2026)
Figure 36. Global Ipilimumab Price by Application (2016-2026) & (US$/G)
Figure 37. North America Ipilimumab Sales Market Share by Type (2016-2026)
Figure 38. North America Ipilimumab Sales Market Share by Application (2016-2026)
Figure 39. North America Ipilimumab Sales Market Share by Country (2016-2026)
Figure 40. North America Ipilimumab Revenue Market Share by Country (2016-2026)
Figure 41. United States Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Canada Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Mexico Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Europe Ipilimumab Sales Market Share by Type (2016-2026)
Figure 45. Europe Ipilimumab Sales Market Share by Application (2016-2026)
Figure 46. Europe Ipilimumab Sales Market Share by Country (2016-2026)
Figure 47. Europe Ipilimumab Revenue Market Share by Country (2016-2026)
Figure 48. Germany Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. France Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. United Kingdom Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Russia Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Italy Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Asia-Pacific Ipilimumab Sales Market Share by Region (2016-2026)
Figure 54. Asia-Pacific Ipilimumab Sales Market Share by Application (2016-2026)
Figure 55. Asia-Pacific Ipilimumab Sales Market Share by Region (2016-2026)
Figure 56. Asia-Pacific Ipilimumab Revenue Market Share by Region (2016-2026)
Figure 57. China Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Japan Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Korea Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. India Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Southeast Asia Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Australia Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South America Ipilimumab Sales Market Share by Type (2016-2026)
Figure 64. South America Ipilimumab Sales Market Share by Application (2016-2026)
Figure 65. South America Ipilimumab Sales Market Share by Country (2016-2026)
Figure 66. South America Ipilimumab Revenue Market Share by Country (2016-2026)
Figure 67. Brazil Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Argentina Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Middle East & Africa Ipilimumab Sales Market Share by Type (2016-2026)
Figure 70. Middle East & Africa Ipilimumab Sales Market Share by Application (2016-2026)
Figure 71. Middle East & Africa Ipilimumab Sales Market Share by Country (2016-2026)
Figure 72. Middle East & Africa Ipilimumab Revenue Market Share by Country (2016-2026)
Figure 73. Turkey Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Egypt Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. South Africa Ipilimumab Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Sales Channel: Direct Channel vs Indirect Channel
Figure 78. Methodology
Figure 79. Research Process and Data Source
α-アドレナリン受容体拮抗薬の世界市場2018-2025 α-adrenoreceptor antagonists are a class of pharmacological agents that act as antagonists on α-adrenergic receptors (α-adrenoceptors).In 2018, the global α-adrenoreceptor Antagonists market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. In this…- ビタミンK拮抗薬（VKA）の世界市場2018-2025 Vitamin K is a kind of substance with biological activity of leaf green quinone.Rising demand from Asia-Pacific region a major driver for the growth of the market. In 2018, the global Vitamin K Antagonists (VKA) market size was xx million US$ and is forecast to xx million US in 2025, growing at a CA…
- 世界のカルシウム拮抗薬市場 2021：企業別、地域別、種類・用途別 The Calcium Antagonists market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations…
- AT1受容体拮抗薬の世界市場2018-2025 AT1 receptor antagonists are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors…
- アンジオテンシン受容体拮抗薬の世界市場2018-2025 Angiotensin II receptor antagonists are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of A…